Three leading scientists in protein science, structural biology and AI will headline the Protein Sciences in Drug Discovery ...

Experimental synaptic restoration compound tazbentetol has demonstrated neuroprotective effects in the retinas of diabetic mice, offering a potential new therapeutic avenue for diabetic retinal ...

TechBio firm WhiteLab Genomics has closed a $26 million Series B round to expand in vivo validation of its AI-designed ...

Penn State researchers have shown that inhibiting the protein VPS34 increases GD2 display on neuroblastoma cell surfaces, ...

As oligonucleotide therapeutics continue to advance, their safety assessment presents challenges that differ from traditional drug modalities. Discover how nonclinical safety studies, evolving ...

A new preclinical study reveals that KRAS-mutant gastric adenocarcinoma fosters a TGF-beta-dependent immunosuppressive tumour ...

A new machine learning-based platform called MALVINA measures bacterial invasion, intracellular accumulation and DNA damage at single-cell resolution, exposing infection dynamics that conventional ...

Dr John Stenson is Product Manager in the Biophysical Characterisation group at Malvern Panalytical, based in the company’s UK headquarters. He holds a PhD in Biochemical Engineering from the ...

Stability problems can derail promising biologics late in development. Bringing high-throughput testing earlier into discovery could help researchers identify risks before they become costly failures.

Researchers at Albert Einstein College of Medicine have identified a cellular recycling pathway whose age-related decline allows senescent 'zombie' cells to evade immune clearance.

Researchers at the University of Birmingham have identified the P2X7 receptor as a key driver of neuroinflammation in human ...

ELRIG Drug Discovery 2026 returns to ExCeL London for its 20th year, with AI, automation and advanced cell models among the technologies set to feature across the two-day programme.